EWING, NJ--(Marketwire - February 15, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a Letter of Intent with BL&H Co., Ltd. (BL&H), a specialty pharmaceutical company based in Seoul, South Korea, pursuant to which BL&H will act as DOR's Sponsor with regard to the administration of a Named Patient Program (NPP) for orBec® to patients suffering from acute gastrointestinal Graft-versus-Host disease (GI GVHD) in South Korea.
